This clinical trial is studying a new treatment called IHL-42X for people with obstructive sleep apnea (OSA), a condition where breathing stops and starts during sleep. The trial has two parts: Phase II and Phase III. In Phase II, the study lasts 4 weeks and will test two different doses of IHL-42X against a placebo (a pill with no medicine) to find the best dose. Phase III lasts 52 weeks and will use the best dose from Phase II, comparing it to the individual ingredients and a placebo.
- Participants cannot use positive airway pressure (PAP)
- Participants must agree not to use cannabis or other recreational drugs during the study.
- Women who can have children need to use two types of birth control, and men should use one to participate.
Eligible participants are 18 or older, must not have certain health conditions, and must not be pregnant or breastfeeding. This study could involve about 120 people in Phase II and around 440 in Phase III. You will need to attend scheduled visits and follow the study's rules to participate.